Physician profile
Michael P Berry
NPI 1093813644
$17,967.29
in general payments reported to CMS, 2019-2025
49 companies · $2,122 in 2025
The $2,122 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,158 · 2020: $1,890 · 2021: $2,944 · 2022: $2,705 · 2023: $2,675 · 2024: $2,472 · 2025: $2,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,249 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,249.07 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,127.26 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,691.55 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $1,643.51 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,486.18 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,313.35 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,023.65 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $952.14 | 2019-2025 | Jardiance, Spiriva Respimat, Ofev |
| Lilly USA, LLC | $945.63 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $611.27 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Amarin Pharma, INC. | $567.93 | 2019-2021 | |
| Astellas Pharma US INC | $559.39 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $540.00 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $500.21 | 2019-2024 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $312.70 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $243.47 | 2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.